Abstract

Diabetic retinopathy is the main cause of blindness, and lesion segmentation is an important basic work for the diagnosis of this disease. The main lesions include soft and hard exudates, microaneurysms, and hemorrhages. However, the segmentation of these four types of lesions is difficult because of their variability in size and contrast, and high intertype similarity. Currently, many network models have problems, such as a large number of parameters and complex calculations, and most segmentation models for diabetic retinopathy focus only on one type of lesion. In this study, a lightweight algorithm based on BiSeNet V2 was proposed for the segmentation of multiple lesions in diabetic retinopathy fundus. First, a hybrid attention module was embedded in the semantic branch of BiSeNet V2 for 8- and 16-fold downsampling, which helped reassign deep feature-map weights and enhanced the ability to extract local key features. Second, a ghost feature-mapping unit was used to optimize the traditional convolution layers and further reduce the computational cost. Third, a new loss function based on the dynamic threshold loss function was applied to supervise the training by adjusting the training weights of the high-loss difficult samples, which enhanced the model's attention to small goals. In experiments on the IDRiD dataset, we conducted an ablation study to verify the effectiveness of each component and compared the proposed model, BiSeNet V2-Pro, with several state-of-the-art models. In comparison with the baseline BiSeNet V2, the segmentation performance of BiSeNet V2-Pro improved by 12.17 %, 11.44 %, and 8.49 % in terms of Sensitivity (SEN), Intersection over Union (IoU), and Dice coefficient (DICE), respectively. Specifically, IoU of MA reaches 0.5716. Compared with other methods, the segmentation speed was significantly improved while ensuring segmentation accuracy, and the number of model parameters was lower. These results demonstrate the superiority of BiSeNet V2-Pro in the multi-lesion segmentation of diabetic retinopathy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call